Evidence map›Paper›PMID 29649958›Full record

ArticleRNA biology2019

The nuts and bolts of the Haloferax CRISPR-Cas system I-B.

Lisa-Katharina Maier, Aris-Edda Stachler, Jutta Brendel, Britta Stoll, Susan Fischer, Karina A Haas, Thandi S Schwarz, Omer S Alkhnbashi, Kundan Sharma, Henning Urlaub and 3 more

Open access · hybridAbstract read
In one paragraph

Article in RNA biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. CRISPR-Cas targeting inmicroLife · 2026
    Article
  3. Article
  4. Article
  5. Provirus deletion frommicroLife · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Progress and Challenges in Archaeal Genetic Manipulation.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. A Small RNA Is Linking CRISPR-Cas and Zinc Transport.Frontiers in molecular biosciences · 2021
    Article
  18. Cellular and Genomic Properties ofFrontiers in microbiology · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Lisa-Katharina Maiera Biology II, Ulm University , Ulm , Germany.
Aris-Edda Stachlera Biology II, Ulm University , Ulm , Germany.
Jutta Brendela Biology II, Ulm University , Ulm , Germany.
Britta Stolla Biology II, Ulm University , Ulm , Germany.
Susan Fischera Biology II, Ulm University , Ulm , Germany.
Karina A Haasa Biology II, Ulm University , Ulm , Germany.
Thandi S Schwarza Biology II, Ulm University , Ulm , Germany.
Omer S Alkhnbashic Freiburg Bioinformatics Group, Department of Computer Science , University of Freiburg , Georges-Köhler-Allee 106, Freiburg , Germany.
Kundan Sharmae Max Planck Institute of Biophysical Chemistry , Am Faßberg 11, Göttingen , Germany.
Henning Urlaube Max Planck Institute of Biophysical Chemistry , Am Faßberg 11, Göttingen , Germany.
Rolf Backofenc Freiburg Bioinformatics Group, Department of Computer Science , University of Freiburg , Georges-Köhler-Allee 106, Freiburg , Germany.
Uri Gophnah School of Molecular Cell Biology & Biotechnology, George S. Wise, Faculty of Life Sciences, Tel Aviv University , Tel Aviv , Israel.
Anita Marchfeldera Biology II, Ulm University , Ulm , Germany.
Universität Ulm · DEUniversity of Freiburg · DELudwig Cancer Research · GBMax Planck Institute for Biophysical Chemistry · DETel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invading genetic elements pose a constant threat to prokaryotic survival, requiring an effective defence. Eleven years ago, the arsenal of known defence mechanisms was expanded by the discovery of the CRISPR-Cas system. Although CRISPR-Cas is present in the majority of archaea, research often focuses on bacterial models. Here, we provide a perspective based on insights gained studying CRISPR-Cas system I-B of the archaeon Haloferax volcanii. The system relies on more than 50 different crRNAs, whose stability and maintenance critically depend on the proteins Cas5 and Cas7, which bind the crRNA and form the Cascade complex. The interference machinery requires a seed sequence and can interact with multiple PAM sequences. H. volcanii stands out as the first example of an organism that can tolerate autoimmunity via the CRISPR-Cas system while maintaining a constitutively active system. In addition, the H. volcanii system was successfully developed into a tool for gene regulation.

Indexed as

Base SequenceCRISPR-Associated ProteinsCRISPR-Cas SystemsHaloferaxRNA, ArchaealTranscription, GeneticCRISPR-Associated ProteinsRNA, ArchaealArchaeaCRISPR-CasCRISPRiHaloarchaeaself-targetingtype I-B

Identifiers

PMID29649958
PMCPMC6546412
OpenAlexW2796988636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.